as 04-02-2025 4:00pm EST
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
Founded: | 2017 | Country: | United States |
Employees: | N/A | City: | RICHMOND |
Market Cap: | 5.3M | IPO Year: | 2020 |
Target Price: | N/A | AVG Volume (30 days): | 8.1M |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -311.18 | EPS Growth: | N/A |
52 Week Low/High: | $4.11 - $35000.00 | Next Earning Date: | 05-19-2025 |
Revenue: | $133,985 | Revenue Growth: | -71.70% |
Revenue Growth (this year): | 95.61% | Revenue Growth (next year): | 1584.79% |
ADTX Breaking Stock News: Dive into ADTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 hours ago
Business Wire
11 hours ago
Business Wire
5 days ago
PR Newswire
9 days ago
Business Wire
9 days ago
GlobeNewswire
15 days ago
Business Wire
16 days ago
Business Wire
21 days ago
The information presented on this page, "ADTX Aditxt Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.